Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans.

Thomson PD, Melmon KL, Richardson JA, Cohn K, Steinbrunn W, Cudihee R, Rowland M.

Ann Intern Med. 1973 Apr;78(4):499-508. No abstract available.

PMID:
4694036
2.

The influence of heart failure, liver disease, and renal failure on the disposition of lidocaine in man.

Thomson PD, Rowland M, Melmon KL.

Am Heart J. 1971 Sep;82(3):417-21. No abstract available.

PMID:
5565429
3.

Influence of congestive heart failure on blood vessels of lidocaine and its active monodeethylated metabolite.

Halkin H, Meffin P, Melmon KL, Rowland M.

Clin Pharmacol Ther. 1975 Jun;17(6):669-76.

PMID:
1139858
4.

Disposition kinetics of lidocaine in normal subjects.

Rowland M, Thomson PD, Guichard A, Melmon KL.

Ann N Y Acad Sci. 1971 Jul 6;179:383-98. No abstract available.

PMID:
5285383
5.

Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.

De Martin S, Orlando R, Bertoli M, Pegoraro P, Palatini P.

Clin Pharmacol Ther. 2006 Dec;80(6):597-606.

PMID:
17178261
6.

Pharmacokinetics of furosemide in advanced renal failure.

Huang CM, Atkinson AJ Jr, Levin M, Levin NW, Quintanilla A.

Clin Pharmacol Ther. 1974 Oct;16(4):659-66. No abstract available.

PMID:
4422027
7.

[Pharmacokinetics of lidocaine after intravenous and oral administration in patients with liver cirrhosis].

Fuchshofen M, Zilly W, Epping J, Richter E.

Verh Dtsch Ges Inn Med. 1978;(84):1110-2. German. No abstract available.

PMID:
741898
8.

Pharmacokinetics of buflomedil after intravenous administration in patients with chronic renal failure.

Rey E, d'Athis P, Richard MO, Fillastre JP, Olive G.

Int J Clin Pharmacol Ther Toxicol. 1984 Dec;22(12):648-52.

PMID:
6526539
9.

The pharmacokinetics and pharmacodynamics of the diuretic bumetanide in hepatic and renal disease.

Marcantonio LA, Auld WH, Murdoch WR, Purohit R, Skellern GG, Howes CA.

Br J Clin Pharmacol. 1983 Feb;15(2):245-52.

10.

[Aspects of water-electrolyte metabolism studied with muscle needle-biopsy. Findings in cardiac insufficiency, hepatic cirrhosis, diabetes mellitus and chronic renal insufficiency].

Ossi E, Mioni G, D'Angelo A, Lupo A, Valvo E, Maschio G.

G Clin Med. 1974 Feb;55(2):131-44. Italian. No abstract available.

PMID:
4419276
11.

Continuous infusion of lidocaine in patients with cardiac arrhythmias. Unpredictability of plasma concentrations.

Sawyer DR, Ludden TM, Crawford MH.

Arch Intern Med. 1981 Jan;141(1):43-5.

PMID:
7447583
12.

Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure.

Tilstone WJ, Dargie H, Dargie EN, Morgan HG, Kennedy AC.

Clin Pharmacol Ther. 1974 Aug;16(2):322-9. No abstract available.

PMID:
4853601
13.

Clinical applications of the pharmacokinetics of lidocaine.

Benowitz NL.

Cardiovasc Clin. 1974;6(2):77-101. Review. No abstract available.

PMID:
4613465
14.

Marked prolongation in disappearance half-time of plasma cholecystokinin-octapeptide in patients with hepatic cirrhosis.

Kanayama S, Himeno S, Kurokawa M, Shinomura Y, Kuroshima T, Okuno M, Tsuji K, Higashimoto Y, Ikei N, Hashimura E, et al.

Am J Gastroenterol. 1985 Jul;80(7):557-60.

PMID:
4014106
15.

Metabolism of the viatmin A transporting protein complex. I. Turnover studies in normal persons and in patients with chronic renal failure.

Vahlquist A, Peterson PA, Wibell L.

Eur J Clin Invest. 1973 Jul;3(4):352-62. No abstract available.

PMID:
4760057
16.

Gross impairment of hepatic drug metabolism in a patient with chronic liver disease.

Adjepon-Yamoah KK, Nimmo J, Prescott LF.

Br Med J. 1974 Nov 16;4(5941):387-8. No abstract available.

17.

[Lower amines in the blood and urine in chronic liver and kidney diseases].

Martin R, Pohl A, Rotzsch W.

Dtsch Z Verdau Stoffwechselkr. 1977;37(2):85-8. German. No abstract available.

PMID:
608434
18.

Lignocaine and indocyanine green kinetics in patients following myocardial infarction.

Bax ND, Tucker GT, Woods HF.

Br J Clin Pharmacol. 1980 Oct;10(4):353-61.

19.

Metabolic clearance of human growth hormone in patients with hepatic and renal failure, and in the isolated perfused pig liver.

Cameron DP, Burger HG, Catt KJ, Gordon E, Watts JM.

Metabolism. 1972 Oct;21(10):895-904. No abstract available.

PMID:
5071956
20.

Effect of renal failure and cirrhosis on the pharmacokinetics and neuromuscular effects of rapacuronium administered by bolus followed by infusion.

Fisher DM, Dempsey GA, Atherton DP, Brown R, Abengochea A, Hunter JM.

Anesthesiology. 2000 Dec;93(6):1384-91.

PMID:
11149430

Supplemental Content

Support Center